Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 227

1.

Active surveillance for prostate cancer: past, present and future.

Singer EA, Kaushal A, Turkbey B, Couvillon A, Pinto PA, Parnes HL.

Curr Opin Oncol. 2012 May;24(3):243-50. doi: 10.1097/CCO.0b013e3283527f99. Review.

PMID:
22450149
2.

An evidence review of active surveillance in men with localized prostate cancer.

Ip S, Dahabreh IJ, Chung M, Yu WW, Balk EM, Iovin RC, Mathew P, Luongo T, Dvorak T, Lau J.

Evid Rep Technol Assess (Full Rep). 2011 Dec;(204):1-341. Review.

4.

Screening for prostate cancer: a review of the evidence for the U.S. Preventive Services Task Force.

Chou R, Croswell JM, Dana T, Bougatsos C, Blazina I, Fu R, Gleitsmann K, Koenig HC, Lam C, Maltz A, Rugge JB, Lin K.

Ann Intern Med. 2011 Dec 6;155(11):762-71. doi: 10.7326/0003-4819-155-11-201112060-00375. Epub 2011 Oct 7. Review.

PMID:
21984740
5.

Population-Based Assessment of Determining Treatments for Prostate Cancer.

Chamie K, Williams SB, Hu JC.

JAMA Oncol. 2015 Apr;1(1):60-7. doi: 10.1001/jamaoncol.2014.192.

PMID:
26182305
6.

Quality of life in men undergoing active surveillance for localized prostate cancer.

Bergman J, Litwin MS.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):242-9. doi: 10.1093/jncimonographs/lgs026.

7.

[Active surveillance of low risk prostate cancer].

Lellig K, Beyer B, Graefen M, Zaak D, Stief C.

Urologe A. 2014 Jul;53(7):1031-9. doi: 10.1007/s00120-014-3535-z. German.

PMID:
24957523
8.

Conventional treatments of localized prostate cancer.

Zerbib M, Zelefsky MJ, Higano CS, Carroll PR.

Urology. 2008 Dec;72(6 Suppl):S25-35. doi: 10.1016/j.urology.2008.10.005.

PMID:
19095125
9.

Long-term quality-of-life outcomes after radical prostatectomy or watchful waiting: the Scandinavian Prostate Cancer Group-4 randomised trial.

Johansson E, Steineck G, Holmberg L, Johansson JE, Nyberg T, Ruutu M, Bill-Axelson A; SPCG-4 Investigators.

Lancet Oncol. 2011 Sep;12(9):891-9. doi: 10.1016/S1470-2045(11)70162-0. Epub 2011 Aug 5.

PMID:
21821474
10.

Outcomes in localized prostate cancer: National Prostate Cancer Register of Sweden follow-up study.

Stattin P, Holmberg E, Johansson JE, Holmberg L, Adolfsson J, Hugosson J; National Prostate Cancer Register (NPCR) of Sweden.

J Natl Cancer Inst. 2010 Jul 7;102(13):950-8. doi: 10.1093/jnci/djq154. Epub 2010 Jun 18.

11.

Sexual function with localized prostate cancer: active surveillance vs radical therapy.

van den Bergh RC, Korfage IJ, Roobol MJ, Bangma CH, de Koning HJ, Steyerberg EW, Essink-Bot ML.

BJU Int. 2012 Oct;110(7):1032-9. doi: 10.1111/j.1464-410X.2011.10846.x. Epub 2012 Jan 19.

12.

Who bears the greatest burden of aggressive treatment of indolent prostate cancer?

Mahal BA, Cooperberg MR, Aizer AA, Ziehr DR, Hyatt AS, Choueiri TK, Hu JC, Sweeney CJ, Beard CJ, D'Amico AV, Martin NE, Orio PF 3rd, Trinh QD, Nguyen PL.

Am J Med. 2015 Jun;128(6):609-16. doi: 10.1016/j.amjmed.2014.12.030. Epub 2015 Jan 30.

13.

Prostate cancer: the new landscape.

Moul JW, Mouraviev V, Sun L, Schroeck FR, Polascik TJ.

Curr Opin Urol. 2009 Mar;19(2):154-60. Review.

PMID:
19195129
14.

Active surveillance compared with initial treatment for men with low-risk prostate cancer: a decision analysis.

Hayes JH, Ollendorf DA, Pearson SD, Barry MJ, Kantoff PW, Stewart ST, Bhatnagar V, Sweeney CJ, Stahl JE, McMahon PM.

JAMA. 2010 Dec 1;304(21):2373-80. doi: 10.1001/jama.2010.1720. Erratum in: JAMA. 2011 May 11;305(18):1862.

15.

Population based study of predictors of adverse pathology among candidates for active surveillance with Gleason 6 prostate cancer.

Vellekoop A, Loeb S, Folkvaljon Y, Stattin P.

J Urol. 2014 Feb;191(2):350-7. doi: 10.1016/j.juro.2013.09.034. Epub 2013 Sep 23.

PMID:
24071481
16.

Careful selection and close monitoring of low-risk prostate cancer patients on active surveillance minimizes the need for treatment.

Soloway MS, Soloway CT, Eldefrawy A, Acosta K, Kava B, Manoharan M.

Eur Urol. 2010 Dec;58(6):831-5. doi: 10.1016/j.eururo.2010.08.027. Epub 2010 Aug 20.

PMID:
20800964
17.

Role of active surveillance in the management of localized prostate cancer.

Glass AS, Cooperberg MR, Meng MV, Carroll PR.

J Natl Cancer Inst Monogr. 2012 Dec;2012(45):202-6. doi: 10.1093/jncimonographs/lgs032.

18.

Pathological and biochemical outcomes after radical prostatectomy in men with low-risk prostate cancer meeting the Prostate Cancer International: Active Surveillance criteria.

Mitsuzuka K, Narita S, Koie T, Kaiho Y, Tsuchiya N, Yoneyama T, Kakoi N, Kawamura S, Tochigi T, Habuchi T, Ohyama C, Arai Y.

BJU Int. 2013 May;111(6):914-20. doi: 10.1111/j.1464-410X.2012.11658.x. Epub 2013 Jan 15.

19.

Focal therapy meets prostate cancer.

Lazzeri M, Guazzoni G.

Lancet. 2010 Sep 25;376(9746):1036-7. doi: 10.1016/S0140-6736(10)60594-6. No abstract available.

PMID:
20870082

Supplemental Content

Support Center